253 related articles for article (PubMed ID: 34968756)
21. Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial.
Singh RP; Barakat MR; Ip MS; Wykoff CC; Eichenbaum DA; Joshi S; Warrow D; Sheth VS; Stefanickova J; Kim YS; He F; Cho GE; Wang Y; Emanuelli A
JAMA Ophthalmol; 2023 Dec; 141(12):1152-1160. PubMed ID: 37971723
[TBL] [Abstract][Full Text] [Related]
22. Association Between Visual Acuity and Fluid Compartments with Treat-and-Extend Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis.
Chaudhary V; Holz FG; Wolf S; Midena E; Souied EH; Allmeier H; Lambrou G; Machewitz T; Mitchell P;
Ophthalmol Ther; 2022 Jun; 11(3):1119-1130. PubMed ID: 35303285
[TBL] [Abstract][Full Text] [Related]
23. OUTCOME OF INTRAVITREAL AFLIBERCEPT FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OR WITHOUT SUBRETINAL FLUID AND SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Kim K; Kim ES; Kim Y; Yang JH; Yu SY; Kwak HW
Retina; 2019 Feb; 39(2):303-313. PubMed ID: 29160779
[TBL] [Abstract][Full Text] [Related]
24. Visual and anatomic outcomes of aflibercept treatment in treatment-naive patients with neovascular age-related macular degeneration; real-life data over 24 months.
Makri OE; Tsapardoni FN; Tsekouras IK; Lagogiannis AP; Chairas N; Pallikari A; Pagoulatos DD; Georgakopoulos CD
Hell J Nucl Med; 2019; 22 Suppl 2():55-62. PubMed ID: 31802046
[TBL] [Abstract][Full Text] [Related]
25. Effect of Anti-VEGF Therapy on the Disease Progression of Neovascular Age-Related Macular Degeneration: A Systematic Review and Model-Based Meta-Analysis.
Luu KT; Seal J; Green M; Winskill C; Attar M
J Clin Pharmacol; 2022 May; 62(5):594-608. PubMed ID: 34783362
[TBL] [Abstract][Full Text] [Related]
26. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
Schmidt-Erfurth U; Kaiser PK; Korobelnik JF; Brown DM; Chong V; Nguyen QD; Ho AC; Ogura Y; Simader C; Jaffe GJ; Slakter JS; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Sowade O; Zeitz O; Norenberg C; Sandbrink R; Heier JS
Ophthalmology; 2014 Jan; 121(1):193-201. PubMed ID: 24084500
[TBL] [Abstract][Full Text] [Related]
27. Potential for Treatment Interval Extension in Eyes with nAMD Disease Activity Post Loading Phase in HAWK and HARRIER.
Tadayoni R; Jaffe GJ; Holz FG; Schmidt-Erfurth U; Takahashi K; Cheung CMG; Hariprasad SM; Gedif K; Olsen R; Best C; Igwe F; Kaiser PK
Ophthalmol Ther; 2023 Aug; 12(4):2209-2216. PubMed ID: 37294524
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis.
Schmidt-Erfurth U; Mulyukov Z; Gerendas BS; Reiter GS; Lorand D; Weissgerber G; Bogunović H
Eye (Lond); 2023 Apr; 37(6):1160-1169. PubMed ID: 35523860
[TBL] [Abstract][Full Text] [Related]
29. Early Residual Fluid-Free Status and Long-Term BCVA Outcomes: A Treatment Agnostic, Post Hoc Analysis of Pooled HAWK and HARRIER Data.
Jhaveri C; Wykoff CC; Khanani AM; Eandi CM; Chang A; B G; Gedif KA; Singer M
Am J Ophthalmol; 2022 Apr; 236():12-19. PubMed ID: 34695400
[TBL] [Abstract][Full Text] [Related]
30. Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration.
Holekamp NM; Sadda S; Sarraf D; Guymer R; Hill L; Blotner S; Spicer G; Gune S
Am J Ophthalmol; 2022 Jan; 233():8-17. PubMed ID: 34289338
[TBL] [Abstract][Full Text] [Related]
31. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
Waldstein SM; Simader C; Staurenghi G; Chong NV; Mitchell P; Jaffe GJ; Lu C; Katz TA; Schmidt-Erfurth U
Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
[TBL] [Abstract][Full Text] [Related]
32. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration.
Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693
[TBL] [Abstract][Full Text] [Related]
33. The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration.
Musiał-Kopiejka M; Polanowska K; Dobrowolski D; Krysik K; Wylęgała E; Grabarek BO; Lyssek-Boroń A
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206485
[TBL] [Abstract][Full Text] [Related]
34. Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography.
Clemens CR; Alten F; Termühlen J; Mihailovic N; Rosenberger F; Heiduschka P; Eter N
Graefes Arch Clin Exp Ophthalmol; 2020 Jul; 258(7):1411-1417. PubMed ID: 32306096
[TBL] [Abstract][Full Text] [Related]
35. EFFECT OF RANIBIZUMAB AND AFLIBERCEPT ON RETINAL PIGMENT EPITHELIAL DETACHEMENT, SUBRETINAL AND INTRARETINAL FLUID IN AGE-RELATED MACULAR DEGENERATION.
Sumarová P; Ovesná P; Matušková V; Beránek J; Michalec M; Michalcová L; Autrata D; Vysloužilová D; Chrapek O
Cesk Slov Oftalmol; 2022; 78(4):176-185. PubMed ID: 35922146
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
Monés J; Biarnés M;
Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal Assessment of Ellipsoid Zone Integrity, Subretinal Hyperreflective Material, and Subretinal Pigment Epithelium Disease in Neovascular Age-Related Macular Degeneration.
Ehlers JP; Zahid R; Kaiser PK; Heier JS; Brown DM; Meng X; Reese J; Le TK; Lunasco L; Hu M; Srivastava SK
Ophthalmol Retina; 2021 Dec; 5(12):1204-1213. PubMed ID: 33640493
[TBL] [Abstract][Full Text] [Related]
38. SUSTAINED BIWEEKLY AFLIBERCEPT FOR REFRACTORY NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The Prospective TRISTAR Study.
Schneider EW; Thomas MK; Recchia FM; Reichstein DA; Awh CC
Retina; 2023 May; 43(5):739-746. PubMed ID: 36728874
[TBL] [Abstract][Full Text] [Related]
39. Short-Term Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration on Prior Anti-VEGF Therapy.
Szigiato A; Mohan N; Talcott KE; Mammo DA; Babiuch AS; Kaiser PK; Ehlers JP; Rachitskaya A; Yuan A; Srivastava SK; Sharma S
Ophthalmol Retina; 2024 Jan; 8(1):10-17. PubMed ID: 37673396
[TBL] [Abstract][Full Text] [Related]
40. Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial.
Roberts PK; Vogl WD; Gerendas BS; Glassman AR; Bogunovic H; Jampol LM; Schmidt-Erfurth UM
JAMA Ophthalmol; 2020 Sep; 138(9):945-953. PubMed ID: 32722799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
